HealthCor Management L.P. trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 26.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,525,000 shares of the company’s stock after selling 562,110 shares during the quarter. Neurocrine Biosciences accounts for 3.9% of HealthCor Management L.P.’s portfolio, making the stock its 11th largest position. HealthCor Management L.P. owned approximately 1.72% of Neurocrine Biosciences worth $118,325,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in NBIX. Dimensional Fund Advisors LP boosted its position in shares of Neurocrine Biosciences by 6.5% during the second quarter. Dimensional Fund Advisors LP now owns 176,197 shares of the company’s stock worth $8,105,000 after purchasing an additional 10,782 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of Neurocrine Biosciences by 3.2% during the third quarter. Nationwide Fund Advisors now owns 124,351 shares of the company’s stock worth $7,620,000 after purchasing an additional 3,800 shares in the last quarter. Crossmark Global Holdings Inc. bought a new stake in Neurocrine Biosciences in the 3rd quarter valued at $286,000. Finally, State Board of Administration of Florida Retirement System lifted its position in Neurocrine Biosciences by 0.7% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock valued at $7,380,000 after acquiring an additional 810 shares in the last quarter.
Shares of Neurocrine Biosciences, Inc. (NBIX) opened at $92.43 on Monday. The company has a debt-to-equity ratio of 0.99, a current ratio of 10.20 and a quick ratio of 10.20. Neurocrine Biosciences, Inc. has a 52 week low of $39.21 and a 52 week high of $92.98.
In other Neurocrine Biosciences news, insider Darin Lippoldt sold 15,237 shares of Neurocrine Biosciences stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $75.00, for a total value of $1,142,775.00. Following the sale, the insider now directly owns 28,394 shares in the company, valued at approximately $2,129,550. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin Charles Gorman sold 3,750 shares of Neurocrine Biosciences stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $78.89, for a total transaction of $295,837.50. The disclosure for this sale can be found here. Insiders sold a total of 399,589 shares of company stock worth $32,443,795 over the last quarter. Company insiders own 4.80% of the company’s stock.
Several equities research analysts recently commented on NBIX shares. Oppenheimer set a $100.00 price objective on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Wednesday, February 14th. Needham & Company LLC boosted their price objective on shares of Neurocrine Biosciences to $95.00 and gave the company a “buy” rating in a research report on Tuesday, January 16th. Deutsche Bank boosted their price objective on shares of Neurocrine Biosciences to $97.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. BidaskClub raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 31st. Finally, Leerink Swann boosted their price objective on shares of Neurocrine Biosciences from $90.00 to $96.00 and gave the company an “outperform” rating in a research report on Tuesday, February 20th. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Neurocrine Biosciences has an average rating of “Buy” and a consensus target price of $92.38.
COPYRIGHT VIOLATION NOTICE: “Neurocrine Biosciences, Inc. (NBIX) Stake Decreased by HealthCor Management L.P.” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/03/12/neurocrine-biosciences-inc-nbix-stake-decreased-by-healthcor-management-l-p.html.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.